title: Effects of dipyridamole on the short-term evolution of glomerulonephritis.
abstract: The aim of the present study is to evaluate the effect of dipyridamole (300 mg/day) versus placebo in a double-blind randomized trial on membranous glomerulonephritis (M-GMN), mesangial IgA glomerulonephritis (IgA-GMN), and segmentary and focal hyalinosis glomerulonephritis (SFH-GMN) during the first 3 months of treatment. In the case of M-GMN, proteinuria dropped by 60% of the basal value in patients treated with dipyridamole; in the case of IgA-GMN it dropped by 65-70%; and in the case of SFH-GMN it dropped by 40% of the basal value. Inhibition of proteinuria in M-GMN was correlated to platelet response, and above all, to the ADP-induced platelet aggregation in whole blood.
authors.affiliation: Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Camara
authors.forename: J P
authors.initials: JP
authors.lastname: de la Cruz
authors.forename: M A
authors.initials: MA
authors.lastname: Frutos
authors.forename: P
authors.initials: P
authors.lastname: Sanchez
authors.forename: E
authors.initials: E
authors.lastname: Lopez de Novales
authors.forename: E
authors.initials: E
authors.lastname: Sanchez
authors.forename: F
authors.initials: F
authors.lastname: Sanchez de la Cuesta
mesh_terms: D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D013997:Time Factors
chemical_list: D004176:Dipyridamole